🇺🇸 FDA
Patent

US 12037616

Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions

granted A61PA61P3/00

Quick answer

US patent 12037616 (Methods and compositions for treating angiopoietin-like 3 (ANGPTL3) related conditions) held by CRISPR THERAPEUTICS AG expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P3/00